Stock Analiz

iSpecimen Inc. ISPC

Biotechnology: Commercial Physical & Biological Resarch · IPO 2021 · data as of November 13, 2026

$0.66Market cap $4M
Open the interactive analysis →

iSpecimen Inc. (ISPC) is a healthcare company listed in the US with a market value of about $4M. In the twelve months to June 30, 2026 it had revenue of $466302 and net income of -$11M, a net margin of -2449.0%.

Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (1/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of -25% a year, a 5-year average ROIC of -126%.

About iSpecimen

iSpecimen is listed in the US and classified in biotechnology: commercial physical & biological resarch, IPO year 2021. Revenue went from $8M in 2020 to $2M in 2025, a decline of about 25.1% a year. It was profitable in 0 of the last 6 years in our data. Its share count rose by 941% over three years (dilution for shareholders).

Score: 0.4 / 5

Value0/5
Future growth0/5
Track record0/5
Financial health1/5
Shareholder returns1/5

Checks passed

  • More cash than debt, or low debt to equity
  • Stock-based pay below 5% of revenue

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S7.7
P/B2.1
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-118.7%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-79.2%
Revenue growth (5 yrs, per year)-25.1%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-193.8%
ROIC (5-yr avg.)-126.2%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 6 years

Fiscal yearTTM202520242023202220212020
Revenue$466302$2M$9M$10M$10M$11M$8M
Net income-$11M-$10M-$12M-$11M-$10M-$9M-$5M
Free cash flow—-$4M-$8M-$6M-$6M-$11M-$288806
EPS (diluted)$-2.48$-2.28$-17.58$-24.55$-23.20$-41.80$-99.40
Net margin-2449.0%-543.7%-134.5%-111.8%-98.5%-80.5%-56.8%
ROIC—-211.3%-277.5%-88.8%-39.3%-14.1%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does iSpecimen pay a dividend?

Not currently.

Is iSpecimen a good stock to buy?

We do not give buy or sell advice. iSpecimen scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.